Annex I Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part I			
A, part 2 (i)			
A, part 2 (ii)			
A, part 2 (iii)			
B	x		
C			
E			
F	x		
G			

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: **18.10.2012**

State Party to the Convention: **ROMANIA**

Date of ratification/accession to the Convention: 1979

National point of contact: **Mrs. Nineta Barbulescu, Director, Directorate OSCE, Assymmetrical Risks and Nonproliferation, Ministry of Foreign Affairs, tel:+40.21.431.12.62; fax:+40.21.319.23.67; e-mail: nineta.barbulescu@mae.ro**

Active promotion of contacts

The Third Review Conference agreed that States parties continue to implement the following:

"Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis."

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, the Seventh Review Conference encouraged States parties to share forward looking information, to the extent possible,

- on planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention, and

- on other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention,

including through the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs.

Confidence-Building Measure "A"

Part 1Exchange of data on research centres and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention."

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO[1] Laboratory Biosafety Manual and/or OIE[2] Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Exchange of data on research centres and laboratories[3]

1. Name(s) of facility[4] **Military Medical Research Center**
2. Responsible public or private organization or company **Ministry of National Defence**
3. Location and postal address **Bucharest, C.A.Rosetti street, No.37, Sect. 2**

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

   - Wholly financed by the Ministry of National Defence

5. Number of maximum containment units[5] within the research centre and/or laboratory, with an indication of their respective size (m^2)

   - NO

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

   - Nothing to report

[1] World Health Organization
[2] World Organization for Animal Health
[3] The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
[4] For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".
[5] In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[6] on a State Party's territory:

Biosafety level 3[7]	**no (35 sqM – under construction)**
Biosafety level 2[8] (if applicable)	**yes (52 sqM)**

Any additional relevant information as appropriate:

- For daily activities, the specialists work in the level 2+ laboratory.

- Due to financial constraints, the maximum containment unit (BSL 4; 11 sqM) reported as being under construction in the previous reports, has been changed to BSL 3 level; at the moment there are two BSL 3 laboratories under construction (35 sqM totally).

[6] Microorganisms pathogenic to humans and/or animals

[7] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[8] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Part 2Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

- Nothing to report

States Parties will make declarations in accordance with the attached forms, which require the following information:

(1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxicology, physical protection, decontamination and other related research;

(2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;

(3) The organizational structure of the programme and its reporting relationships; and

(4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;

(a) location;

(b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;

(c) the total number of staff employed, including those contracted full time for more than six months;

(d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;

(e) a list of the scientific disciplines of the scientific/engineering staff;

(f) the source and funding levels in the following three areas: research, development, and test and evaluation; and

(g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxicology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxicology, physical protection, decontamination and other related research.

- prophylaxis: vaccinology;
- studies on pathogenicity and virulence: No;
- diagnostic techniques: PCR, ELISA, MS MALDI TOF, IF, HAI, MiniApi, microscopy etc.;
- aerobiology: No;
- detection: No;
- treatment: antibacterial resistance;
- toxinology: SEB, botulinum toxin, ricinotoxin, aflatoxin (diagnostic and identification);
- physical protection: No;
- decontamination: new substances for decontamination bio-chem;
- and other related research: antiterrorist exercise in field.

The objective of research was to find out new approaches, diagnostic methods, prophylaxis and treatment for troops protection against biological weapons.

2. State the total funding for each programme and its source.

-Total funding in 2011 - 12700 EURO;
-Source of funding - Ministry of National Defence.

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

-No.

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

   - Microbiological and epidemiological Branch/ Military Medical Research Center

2. Where is it located (include both address and geographical location)?

   - Military Medical Research Center- Bucharest, C.A. Rosetti Street, No.37, Sect. 2, and external facility "Cernica Fort" Bucharest

3. Floor area of laboratory areas by containment level:

   BL2 **52 sqM**

   BL3 **35 sq M (under construction)** (sqM)

   BL4 _____ (sqM)

   Total laboratory floor area **87 sqM**

4. The organizational structure of each facility.

(i) Total number of personnel - **11**

(ii) Division of personnel:

Military - **0**

Civilian - **11**

(iii) Division of personnel by category:

Scientists - **6**

Engineers - **0**

Technicians - **5**

Administrative and support staff - **0**

(iv) List the scientific disciplines represented in the scientific/engineering staff.

- Microbiology

- Epidemiology

- Veterinary

(v) Are contractor staff working in the facility? If so, provide an approximate number.

- Nothing to report

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

- 100% Ministry of National Defence

(vii) What are the funding levels for the following programme areas:

Research - **12700 EURO**

Development - **0**

Test and evaluation - **0**

(viii) Briefly describe the publication policy of the facility:

- Unclassified

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

-Iordache, P. Zamora; Lungu, R. M.; Epure, G.; Muresan, M.; Petre, R.; Petrea, N.; Pretorian, Á.; Dionezie, B.; Mutihac, L.; Ordeanu, V. ***The Determination of the Nanostructured Materials' Morphology, by Applying the Statistics of the Structural Element Maps,*** **Source: JOURNAL OF OPTOELECTRONICS AND ADVANCED MATERIALS Volume: 13 Issue: 5-6 Pages: 550-559 Published: MAY-JUN 2011 Cited in Web of Science ISSN: 1454-4164**

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms[9] and/or toxins studied, as well as outdoor studies of biological aerosols.

Bacillus anthracis

Brucella spp

West Nile Virus

TBE Virus

Aflatoxins

Testing for biological agents(stimulators) decontamination in field (Training team NBC Defence).

[9] Including viruses and prions.

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research.

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Published papers 2011

Danes Mihai, Carmen Moisoiu, Mihaela Scripcariu, Rodica Moise, Doina Danes, Doina Surugiu 2011, A commercial disinfectant efficacy against vaccinia virus, Romanian Journal of Veterinary Medicine 4: 181-190

(Eficacitatea unui dezinfectant comercial fata de virusul vaccinia, Revista Romana de Medicina Veterinara 4 :181 – 190)

Cismileanu Ana, Daniela Lorin 2011, Experimental model to validate the ELISA method determination of deoxynivalenol in feed, Romanian Journal of Veterinary Medicine 3: 23-30

(Model experimental pentru validarea metodei ELISA de determinare a deoxinivalenolului din furaje, Revista Romana de Medicina Veterinara 3: 23 – 30)

Csuma Ana, Victorița Burghelea, Ana Cismileanu 2011, Identification and determination of compound feed of banned feed additives for use in animal feed production, Academy of Agricultural and Forestry Sciences, Scientific research offer for tehnological transfer in agriculture, food industry and forestry, Ed. New Agris ISSN 1844-0355 (*in press*)

(Identificarea si determinarea din nutreturi combinate a unor aditivi furajeri interzisi pentru utilizare în hrana animalelor de productie, Academia de Stiinte Agricole si Silvice, Oferta cercetarii stiintifice pentru transfer tehnologic in agricultura, industria alimentara si silvicultura, Ed. New Agris ISSN 1844-0355 (*in press*)

Csuma Ana, Victorița Burghelea, Ana Cismileanu 2011, Determination of coccidiostats nicarbazin, diclazuril and robenidine of compound feed for poultry, Academy of Agricultural and Forestry Sciences, Scientific research offer for tehnological transfer in agriculture, food industry and forestry, Ed. New Agris ISSN 1844-0355 (*in press*)

(Determinarea coccidiostaticelor nicarbazin, diclazuril si robenidina din nutreţuri combinate pentru pasari, Academia de

Stiinte Agricole si Silvice, Oferta cercetarii stiintifice pentru transfer tehnologic in agricultura, industria alimentara si silvicultura, Ed. New Agris ISSN 1844-0355 (*in press*)

List of 2011 ISI articles INCDMI "Cantacuzino"

1. Adriaenssens N, Coenen S, Kroes AC, Versporten A, Vankerckhoven V, Muller A, Blix HS, Goossens H; ESAC Project Group (Baicus A). European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe, J Antimicrob Chemother. 66(8):1897-905, 2011

2. Baicus A, Persu A, Dinu S, Joffret ML, Delpeyroux F, Oprisan G. The frequency and biodiversity of poliovirus and non-polio enterovirus strains isolated from healthy children living in a limited area in Romania. Arch Virology, 156(4):701-706, 2011

3. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group (Lemeni D). Clostridium difficile infection in Europe: a hospital-based survey. Lancet, 377(9759):63-73, 2011

4. Chifiriuc MC, Banu O, Bleotu C, Lazar V Interaction of bacteria isolated from clinical biofilms with cardiovascular prosthetic devices and eukaryotic cells, Anaerobe. 2011 (online)

5. Chifiriuc MC, Pircalabioru G, Gîlea B, Lazar V, Dascalu L, Enache G, Bleotu C. Immunogenicity of different cellular fractions of Vibrio parahaemolyticus strains grown under sub-lethal heat and osmotic stress. African Journal of Microbiology Research, 5(1) 65-72,2011

6. Coipan E.C., Vladimirescu Al.F. Ixodes ricinus ticks (Acari: Ixodidae) - vectors for Lyme disease spirochetes in Romania. Experimental and Applied Acarology, 54 (3): 293-300, 2011

7. Cotar AI, Badescu D, Oprea M, Dinu S, Banu O, Dobreanu D, Dobreanu M, Ionac A, Flonta M, Straut M. "Q fever endocarditis in Romania: the first cases confirmed by direct sequencing". Int. J. Mol. Sci. 12, 2011
Ferdes, M; Ungurcanu, C; Mihalcea, A; Chirvase, AA; Mocanu, E, The Influence of the Carbon Source on Torularhodin Pigment Biosynthesis. Rev.Chim., 62 (3), 339-343, 2011.

8. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jimenez-Jorge S, Savulescu C, Ciancio BC, Moren A. I-MOVE Multi-Centre Case Control Study 2010-2011: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. PloS ONE, 6(11), 2011

9.Limban C, Marutescu L, Chifiriuc MC Synthesis, spectroscopic properties and antipathogenic activity of new thiourea derivatives. Molecules. 16(9):7593-607, 2011

10. Limban C, Missir AV, Chirita IC, Nitulescu GM, Caproiu MT, Chifiriuc MC, Israil AM. Synthesis and antimicrobial properties of new 2-((4- ethylphenoxy) methyl)benzoylthioureas. Chemical Papers, 65 (1) 60–69, 2011

11. Maftei I, Segal L, Panculescu-Gatej R, Ceianu C, Covic A. Hantavirus infection- hemorrhagic fever with renal syndrome: the first case series reported in Romania and review of literature. Int Urol Nephrol . (DOI 10.1007/s11255-011-0013-z, 2011 (Ahead of print publication)

12. Mankertz A, Mihneva Z, Gold H, Baumgarte S, Baillot A, Helble R, Roggendorf H, Bosevska G, Nedeljkovic J, Makowka A, Hutse V, Holzmann H, Aberle SW, Cordey S, Necula G, Mentis A, Korukluoğlu G, Carr M, Brown KE, Hübschen JM, Muller CP, Mulders MN, Santibanez S, Spread of Measles Virus D4-Hamburg, Europe, 2008–2011. Emerg Infect Dis 17(8):1396-401, 2011.

13. Stavri H, Ulea I, Radu DL, Gheorghiu Branaru M, Moldovan O, Bogdan MA, Tudose C, Raileanu M, Duiculescu D, Ene L, Olar V, Ionita C, Popa GL, Popa MI, Brennan PJ, "Serodiagnosis of environmental mycobacterial infections", J Microbiol Methods 86, 283–290, 2011

14. Valenciano, M; Kissling, E; Cohen, JM; Oroszi, B; Barret, AS; Rizzo, C; Nunes, B; Pitigoi, D; Camara, AL; Mosnier, A; Horvath, JK; O'Donnell, J; Bella, A; Guiomar, R; Lupulescu, E; Savulescu, C; Ciancio, BC; Kramarz, P; Moren, A. Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009-2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLOS Med, 8 (1):e1000388, 2011.

15. M. Straut, S. Dinu, M. Surdeanu – "Point mutations associated with antibiotic resistance and clonal relatedness of Pseudomonas aeruginosa clinical isolates" – Poster. 21st ECCMID & 27thICC, Milan, Italy 7-10 May 2011 (Abstract: Clin. Microbiol. Infect. 2011, 17: S4, S133)

16. C Usein, D Tatu-Chitoiu, S Ciontea, M Baltoiu, M Nica, M Damian. "Enteroaggregative Escherichia coli as a possible cause of sporadic diarrhoea in children from Romania". 21st ECCMID&27thICC, Milan, Italy 7-10 May 2011 (Abstract: Clin. Microbiol. Infect. 2011, 17: S4, 756)

17. Gheorghe Necula, Maria E. Mihai, Claudiu E. Sbarcea, Sorin Dinu, Emilia Lupulescu, Emanoil Ceausu, Adrian Streinu-Cercel, Dan F. Mihailescu, Viorel I. Alexandrescu, Romanian Review of Laboratory Medicine, Overview of influenza virus antiviral resistance in Romania in the last four epidemic seasons phenotyping, genotyping and molecular analysis study, Vol. 19, No. 3, September 2011.

18. Vicente JL, Sousa CA, Alten B, Caglar SS, Fălcuță E, Latorre JM, Toty C, Barré H, Demirci B, Di Luca M, Toma L, Alves R, Salgueiro P, Silva TL, Bargues MD, Mas-Coma S, Boccolini D, Romi R, Nicolescu G, do Rosário VE, Ozer N, Fontenille D, Pinto J, Genetic and phenotypic variation of the malaria vector Anopheles atroparvus in southern Europe. Malar J, 10: 5, 201

Scientific meetings 2011

Csuma Ana, Cornelia Pîrlog 2011, Some aspects regarding impurities profile in Fipronil – HPLC method , The XI National Congress of Veterinary Medicine, Bucharest May 8 to 11, 2011

Militaru D.,Virgilia Popa, Daniela Botus, Beatrice Stirbu 2011, Designing of classical and real time PCR format assays for detection and quantification of Neospora caninum in biological samples (i), The XI National Congress of Veterinary Medicine, Bucharest May 8 to 11, 2011

Popa Virgilia, Daniela Botus, Irina Codita, Vasilica Ungureanu, Lucreția Negrariu, Catălina Gheorghe, Carmen Moisoiu, Florin Pastramă, Ionut Sorescu, Nicolae Catana, Gheorghe Rapuntean 2011, In vitro testing of antibiotic associations, The XI National Congress of Veterinary Medicine, Bucharest May 8 to 11, 2011

Popa Mirela, Miliana Petrof, Virgilia Popa 2011, Pathotyping of Salmonella strains, FVM Symposium Bucharest, November 17 to 18. 2011,
(Patotipizarea tulpinilor de Salmonella, Simpozionul FMV Bucuresti, 17-18 nov. 2011)

Popa Mirela, Miliana Petrof, Virgilia Popa 2011, Selection of vaccine strains and their impact on canine parvovirus population circulating in Romania, Bucharest IDAH Symposium, October 11 to 12. 2011
(Selectia tulpinilor vaccinale si impactul lor asupra populatiei circulante de parvovirus canin pe teritoriul Romaniei, Simpozionul IDSA Bucuresti 11-12 oct. 2011)

International cooperation in scientific research

List of the projects from "Pasteur Institute"

Responsible from Pasteur Institute	Project	Cooperation
Virgilia Popa / Mihai Danes	Discontools, A European technology platform for global animal health, Development of the most effective tools to control infectious diseases in animals.	FP7-KBBE-2007-1

List of 2011 ongoing or finalized projects INCDMI "Cantacuzino"

Label CF#	Start date	End date	Project leader	Project title	Call name	Name of contracting authority
CF1	2009	2012	PITIGOI DANIELA	SE-Stockholm: ECDC country inventory and activities support 2009/S 183-262603	ECDC/08/025	European Commission - DG SANCO - ECDC
CF2	2009	2012	RADU DOREL	Genetic subtypes and antiretroviral drug resistance of HIV-1 in Romania.		Walter Reed Army Research Institute, USA
CF3	2009	2012	ALEXANDRESCU VIOREL	I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness)	EpiConcept (Franta) (Contract OJ/2007/015)	European Commission – DG SANCO – ECDC
CF4	08.2009	12.2011	DAMIAN MARIA	Surveillance of Diphtheria (RIIPDIPHT)	ACIP 2009	Institut Pasteur International Network
CF5	2009	2011	RADU DOREL	Influenza Vaccine Production Capacity Building		WHO
CF6	04.10	2014	RADU DOREL	FASTVAC: A generic framework for FAST production and evaluation of emergency VACcines.		European Commission – DG SANCO
CF7	2010	2012	ONU ADRIAN	Development and Sustainable Manufacturing of Adjuvanted Pandemic Influenza Vaccines in Developing Countries.	F 16 SUB - 2010 BARDA 1 IDSE P 100008-01-00	ASPR/BARDA/AMS
CF8	01.11	12.14	CEIANU CORNELIA	Biology and control of vector-borne infections in Europe.	FP7	European Commission – DG Research (FP7)
CF9	10.07	10.12	RADU DOREL	Development of a Novel Immunoassay for the Very Early Detection of Biothreatening Bacterial Infection.		NATO ScfP
CF10	06.07	12.11	OPRISAN GABRIELA	Interrelationships of Hepatitis Viruses Genotypes and/or Variants with the Environment: Evolution of their Respective Clinical and genetic Impacts on Primary Liver Cancer Development in Central and Eastern Europe	ACIP 2007	Institut Pasteur International Network
CF11	09.11	08.12	DAMIAN Maria	Improvement of laboratory diagnosis of Pertussis in Romania		Private funds: Sanofi Pasteur-Romania
CF12	09.10	09.12	SALAGEANU AURORA	Development of Research Infrastructure in Microbiology, Immunology and Biotechnology for an Increase Capacity in Investigating Diseases with Major Impact on Public Health	POSCCE 2009	ANCS-OIC

F48	09.08	09.11	SALAGEANU AURORA	Design and development of innovative biotechnologies for obtaining therapeutical extracts from Monascus sp. (partner)	PNII _Partnership in Priority Domains 2008	CNMP
F49	09.08	11.11	UNGUREANU VASILICA	Management of acute bacterial meningitis: modern investigative and intervening strategies	PNII _Partnership in Priority Domains 2008	CNMP
F50	09.08	11.11	STRAUT MONICA	Bacterial infective endocarditis – development of a functional model for surveillance and characterization of aetiological microorganisms, based on molecular and immunological methods	PNII _Partnership in Priority Domains 2008	CNMP
F51	09.08	12.11	PURCAREA CIULACU VALERIA	Multidisciplinary national strategies for early warning, monitoring and control of emergent and re-emergent diseases transmitted by mosquitoes vectors (dipter: Culicidae),	PNII _Partnership in Priority Domains 2008	CNMP
F52	09.08	12.11	CREMER LIDIA	New compounds involved in modulating the activity of pro-inflammatory cytokine HMGB-1 target in the treatment of septic shock and malignant neoplastic disease therapy	PNII _Partnership in Priority Domains 2008	CNMP
F53	10.08	09.11	DAMIAN MARIA	Diarrheal syndromes caused by Enterobacteriaceae in the group of age 0-4 years. Molecular studies for diagnosis, pathogenicity, virulence and antibiotic resistance (GEN-INF) (partner).	PNII _Partnership in Priority Domains 2008	CNMP
F54	10.08	09.11	CODITA IRINA	Development of food packaging antimicrobial foils containing natural antimicrobial compounds. (partner)	PNII _Partnership in Priority Domains 2008	CNMP
F55	10.08	10.11	ONU ADRIAN	Advanced multicriterial decision algorithms for inteligent management and preparation of biotechnological therapeutic products for human use (partener}	PNII _Partnership in Priority Domains 2008	CNMP
F56	10.08	10.11	ALEXANDRESCU VIOREL	Molecular investigations of acute respiratory infections due to non-influenza viruses and the implications in newborns and infants pathology.	PNII _Partnership in Priority Domains 2008	CNMP
F57	10.08	10.11	ISRAIL ANCA	Studies regarding the synthesis , physico-chemical characterization and antimicrobial activity testing of some new compounds with tricyclic structure (partner).	PNII _Partnership in Priority Domains 2008	CNMP
F58	10.08	11.11	DAMIAN MARIA	Molecular markers useful for the diagnostic and	PNII _Partnership in	CNMP

				epidemiology of food borne infections caused by Gram-negative bacilli.	Priority Domains 2008	
F59	10.08	11.11	CODITA IRINA	New materials with antimicrobial activity for nosocomial infections control (partner).	PNII _Partnership in Priority Domains 2008	CNMP
F60	10.08	12.11	ISRAIL ANCA	Interdisciplinary studies on solving new features of antibioresistance having a major involvement in cardiovascular and gastroenterological surgical pathologies.	PNII _Partnership in Priority Domains 2008	CNMP
F61	10.08	12.11	DAMIAN MARIA	Molecular characterization of mutations in the gene for blood coagulation factor v in population with thrombophilia risk: genotype-phenotype correlation (partner)	PNII _Partnership in Priority Domains 2008	CNMP
F62	10.08	12.11	DAMIAN MARIA	Optimizing the management of pediatric Helicobacter pylori infections by linking genotyping and genotyping profile for improving short and long term clinical prognosis and outcome (partner).	PNII _Partnership in Priority Domains 2008	CNMP
F63	01.09	12.11	USEIN CODRUTA	Vaginal carriage of potentially pathogenic microorganisms: transitory colonization of first step in releasing an infection.	PNII_Ideas 2008	CNCSIS
F68	07.07	2012	ALEXANDRESCU VIOREL	Capacity building for the control of Avian influenza through technology transfer and training.	FP6	European Commission – DG SANCO

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

(a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures[10]	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equip-ment and means of delivery specified in Article I	Yes	Yes	No	No
(b) Exports of micro-rganisms and toxins	Yes	Yes	No	Yes
(c) Imports of micro-rganisms and toxins	No	No	No	No
Biosafety[12] and biosecurity[13]				

Annex to Form E

Declaration of legislation, regulations. and other measures

No	Specification	No	Year	Topic
1	Regulation (EU) of the European parliament and of the Council	1232	2011	Amending Council regulation (EC) No. 428/2009 setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items
2	Law	197	2011	Approving the Government ordinance No. 119/2010 regarding the control regime of dual use operations
3	Order of the Minister of Foreign Affairs	101	2011	Approving the Regulation for implementing the provisions of Government Ordinance No. 119/2010 regarding the control regime of dual use operations

[10] Including guidelines.
[11] Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.
[12] In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.
[13] In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

Declaration of vaccine production facilities

1. Name of facility: National Society "Pasteur Institute" SA

2. Location (mailing address): 333, Giulesti Str., 060269 Bucharest, sector 6, Romania, tel: +40212206920; fax: +40212206915; email: office@pasteur.ro / biomol.pasteur@pasteur.ro

3. General description of the types of diseases covered: animal diseases (virai, bacterial, parasitic and nutritional diseases).

Declaration of vaccine production facilities

1. Name of facility: "Cantacuzino" National Institute of Research and Development for Microbiology and Immunology

2. Location (mailing address): Splaiul Independenței 103, 050096, Bucharest, Romania Tel: +40.21.306.91.00 ; fax :+40.21.306.93.07 ; e-mail: office@cantacuzino.ro

3. General description of the types of diseases covered: human influenza, tuberculosis.